Prolactinoma differential diagnosis: Difference between revisions

Jump to navigation Jump to search
mNo edit summary
m (Bot: Removing from Primary care)
 
(14 intermediate revisions by 6 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Prolactinoma}}
[[Image:Home_logo1.png|right|250px|link=https://www.wikidoc.org/index.php/Prolactinoma]]
{{CMG}} {{AE}}{{Anmol}}
{{CMG}}; {{AE}} {{Anmol}}


==Overview==
==Overview==
[[Prolactinoma]] must be differentiated from other causes of [[hyperprolactinemia]].
[[Prolactinoma]] must be differentiated from other causes of [[hyperprolactinemia]] that may present as [[galactorrhea]], [[amenorrhea]], (in females) and [[infertility]] (in both males and females). Causes of [[hyperprolactinemia]] can be categorized as [[physiological]], [[pathological]], and [[medication-induced]].
 
Causes of [[hyperprolactinemia]] can be categorized as [[physiological]], [[pathological]] and [[medication-induced]].


==Differential Diagnosis==
==Differential Diagnosis==
[[Prolactinoma]] must be differentiated from other causes of [[hyperprolactinemia]] that may present as [[galactorrhea]], [[amenorrhea]] (in females) and [[infertility]] (in both males and females) including:
[[Prolactinoma]] must be differentiated from other causes of [[hyperprolactinemia]] that may present as [[galactorrhea]], [[amenorrhea]], (in females) and [[infertility]] (in both males and females) including:
*'''Physiological:'''
*'''Physiological:'''
**Normal [[pregnancy]]<ref name="pmid910825">{{cite journal| author=Rigg LA, Lein A, Yen SS| title=Pattern of increase in circulating prolactin levels during human gestation. | journal=Am J Obstet Gynecol | year= 1977 | volume= 129 | issue= 4 | pages= 454-6 | pmid=910825 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=910825  }} </ref>
**Normal [[pregnancy]]<ref name="pmid910825">{{cite journal| author=Rigg LA, Lein A, Yen SS| title=Pattern of increase in circulating prolactin levels during human gestation. | journal=Am J Obstet Gynecol | year= 1977 | volume= 129 | issue= 4 | pages= 454-6 | pmid=910825 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=910825  }} </ref>
Line 16: Line 14:
***[[Somatotroph adenoma]]: [[Acromegaly]]
***[[Somatotroph adenoma]]: [[Acromegaly]]
***[[ACTH-secreting tumor|Corticotroph adenoma]]: [[Cushing's syndrome]]
***[[ACTH-secreting tumor|Corticotroph adenoma]]: [[Cushing's syndrome]]
**Supra [[Sella turcica|seller]] tumors(tumors present in region of [[pituitary stalk]])
**[[Suprasellar tumors]] ([[tumors]] present in the region of the [[pituitary stalk]])
**[[Hypothyroidism]]<ref name="pmid4199418">{{cite journal| author=Snyder PJ, Jacobs LS, Utiger RD, Daughaday WH| title=Thyroid hormone inhibition of the prolactin response to thyrotropin-releasing hormone. | journal=J Clin Invest | year= 1973 | volume= 52 | issue= 9 | pages= 2324-9 | pmid=4199418 | doi=10.1172/JCI107421 | pmc=333037 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=4199418  }} </ref>
**[[Hypothyroidism]]<ref name="pmid4199418">{{cite journal| author=Snyder PJ, Jacobs LS, Utiger RD, Daughaday WH| title=Thyroid hormone inhibition of the prolactin response to thyrotropin-releasing hormone. | journal=J Clin Invest | year= 1973 | volume= 52 | issue= 9 | pages= 2324-9 | pmid=4199418 | doi=10.1172/JCI107421 | pmc=333037 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=4199418  }} </ref>
**[[Chronic renal failure]]<ref name="pmid7372775">{{cite journal| author=Sievertsen GD, Lim VS, Nakawatase C, Frohman LA| title=Metabolic clearance and secretion rates of human prolactin in normal subjects and in patients with chronic renal failure. | journal=J Clin Endocrinol Metab | year= 1980 | volume= 50 | issue= 5 | pages= 846-52 | pmid=7372775 | doi=10.1210/jcem-50-5-846 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=7372775  }} </ref>
**[[Chronic renal failure]]<ref name="pmid7372775">{{cite journal| author=Sievertsen GD, Lim VS, Nakawatase C, Frohman LA| title=Metabolic clearance and secretion rates of human prolactin in normal subjects and in patients with chronic renal failure. | journal=J Clin Endocrinol Metab | year= 1980 | volume= 50 | issue= 5 | pages= 846-52 | pmid=7372775 | doi=10.1210/jcem-50-5-846 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=7372775  }} </ref>
**[[Hepato-biliary diseases|Liver disease]]<ref name="pmid26958514">{{cite journal| author=Jha SK, Kannan S| title=Serum prolactin in patients with liver disease in comparison with healthy adults: A preliminary cross-sectional study. | journal=Int J Appl Basic Med Res | year= 2016 | volume= 6 | issue= 1 | pages= 8-10 | pmid=26958514 | doi=10.4103/2229-516X.173984 | pmc=4765284 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26958514  }} </ref>
**[[Hepato-biliary diseases|Liver disease]]<ref name="pmid26958514">{{cite journal| author=Jha SK, Kannan S| title=Serum prolactin in patients with liver disease in comparison with healthy adults: A preliminary cross-sectional study. | journal=Int J Appl Basic Med Res | year= 2016 | volume= 6 | issue= 1 | pages= 8-10 | pmid=26958514 | doi=10.4103/2229-516X.173984 | pmc=4765284 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26958514  }} </ref>
***[[Cirrhosis]](with or without [[encephalopathy]])
***[[Cirrhosis]] (with or without [[encephalopathy]])
***[[Viral hepatitis]](with [[encephalopathy]])
***[[Viral hepatitis]] (with [[encephalopathy]])
**[[Seizure|Seizure disorder]]<ref name="Ben-Menachem2006">{{cite journal|last1=Ben-Menachem|first1=Elinor|title=Is Prolactin a Clinically Useful Measure of Epilepsy?|journal=Epilepsy Currents|volume=6|issue=3|year=2006|pages=78–79|issn=1535-7597|doi=10.1111/j.1535-7511.2006.00104.x}}</ref><ref name="pmid737437">{{cite journal| author=Trimble MR| title=Serum prolactin in epilepsy and hysteria. | journal=Br Med J | year= 1978 | volume= 2 | issue= 6153 | pages= 1682 | pmid=737437 | doi= | pmc=1608938 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=737437  }} </ref>
**[[Seizure|Seizure disorder]]<ref name="Ben-Menachem2006">{{cite journal|last1=Ben-Menachem|first1=Elinor|title=Is Prolactin a Clinically Useful Measure of Epilepsy?|journal=Epilepsy Currents|volume=6|issue=3|year=2006|pages=78–79|issn=1535-7597|doi=10.1111/j.1535-7511.2006.00104.x}}</ref><ref name="pmid737437">{{cite journal| author=Trimble MR| title=Serum prolactin in epilepsy and hysteria. | journal=Br Med J | year= 1978 | volume= 2 | issue= 6153 | pages= 1682 | pmid=737437 | doi= | pmc=1608938 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=737437  }} </ref>
*'''Medication-induced:'''
*'''Medication-induced:'''
Line 33: Line 31:
***[[Methyldopa]]<ref name="pmid1268617">{{cite journal| author=Steiner J, Cassar J, Mashiter K, Dawes I, Fraser TR, Breckenridge A| title=Effects of methyldopa on prolactin and growth hormone. | journal=Br Med J | year= 1976 | volume= 1 | issue= 6019 | pages= 1186-8 | pmid=1268617 | doi= | pmc=1639736 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=1268617  }} </ref>
***[[Methyldopa]]<ref name="pmid1268617">{{cite journal| author=Steiner J, Cassar J, Mashiter K, Dawes I, Fraser TR, Breckenridge A| title=Effects of methyldopa on prolactin and growth hormone. | journal=Br Med J | year= 1976 | volume= 1 | issue= 6019 | pages= 1186-8 | pmid=1268617 | doi= | pmc=1639736 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=1268617  }} </ref>
***[[Verapamil]]<ref name="pmid6682619">{{cite journal| author=Fearrington EL, Rand CH, Rose JD| title=Hyperprolactinemia-galactorrhea induced by verapamil. | journal=Am J Cardiol | year= 1983 | volume= 51 | issue= 8 | pages= 1466-7 | pmid=6682619 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=6682619  }} </ref>
***[[Verapamil]]<ref name="pmid6682619">{{cite journal| author=Fearrington EL, Rand CH, Rose JD| title=Hyperprolactinemia-galactorrhea induced by verapamil. | journal=Am J Cardiol | year= 1983 | volume= 51 | issue= 8 | pages= 1466-7 | pmid=6682619 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=6682619  }} </ref>
{| class="wikitable"
{|
! colspan="4" |Prolactinoma must be differentiated from causes of hyperprolactinemia
! style="background: #4479BA; text-align: center;" |{{fontcolor|#FFF|Disease}}
! style="background: #4479BA; text-align: center;" |{{fontcolor|#FFF|Clinical Findings}}
! style="background: #4479BA; text-align: center;" |{{fontcolor|#FFF|Laboratory Findings}}
! style="background: #4479BA; text-align: center;" |{{fontcolor|#FFF|Management}}
|-
|-
!Disease
| style="background: #DCDCDC; text-align: center;" |[[Somatotroph adenoma]]:
!Clinical Findings
!Laboratory findings
!Management
|-
|[[Somatotroph adenoma]]:
[[Acromegaly]]
[[Acromegaly]]
|Clinical features of acromegaly are due to high level of [[Growth hormone|human growth hormone]]([[Growth hormone|hGH]]):
| style="background: #F5F5F5;" |Clinical features of [[acromegaly]] are due to high level of [[Growth hormone|human growth hormone]] ([[Growth hormone|hGH]]):
* Soft tissue swelling of the hands and feet
* [[Soft tissue]] [[swelling]] of the hands and feet
 
* Brow and lower jaw protrusion
* Brow and lower jaw protrusion
* Enlarging hands
* Enlarged hands
* Enlarging feet
* Enlarged feet
* [[Arthritis]] and [[carpal tunnel syndrome]]
* [[Arthritis]] and [[carpal tunnel syndrome]]
* Increase in teeth spacing
* Increase in teeth spacing
* [[Macroglossia]] [enlarged tongue]
* [[Macroglossia]] (enlarged tongue)
* [[Heart failure]]
* [[Heart failure]]
* [[Kidney failure]]
* [[Kidney failure]]
* Compression of the [[optic chiasm]] leading to loss of vision in the outer visual fields (typically [[bitemporal hemianopia]])
* Compression of the [[optic chiasma]] leading to loss of [[vision]] in the outer [[visual fields]] (typically [[bitemporal hemianopia]])
* [[Headache]]
* [[Headache]]
* [[Diabetes mellitus]]
* [[Diabetes mellitus]]
* [[Hypertension]]
* [[Hypertension]]
* [[Cardiomegaly]]
* [[Cardiomegaly]]
|
| style="background: #F5F5F5;" |
* Elevated [[insulin-like growth factor-1]] ([[Insulin-like growth factor-I|IGF-1]]) levels
* Elevated [[insulin-like growth factor-1]] ([[Insulin-like growth factor-I|IGF-1]]) levels
* Elevated [[growth hormone]] levels
* Elevated [[growth hormone]] levels
|
| style="background: #F5F5F5;" |
* Medical management:
* Medical management:
** [[Octreotide]]
** [[Octreotide]]
** [[Bromocriptine]]
** [[Bromocriptine]]
* Surgical management:
* Surgical management:
** Endonasal transsphenoidal surgery
** Endonasal transsphenoidal surgery
* Radiation therapy
* [[Radiation therapy]]
|-
|-
|[[ACTH-secreting tumor|Corticotroph adenoma]]: [[Cushing's syndrome]]
| style="background: #DCDCDC; text-align: center;" |[[ACTH-secreting tumor|Corticotroph adenoma]]:
|Clinical features of [[Cushing's syndrome]] are due to increased level of [[cortisol]]:
[[Cushing's syndrome]]
* Rapid [[Obesity|weight gain]], particularly of the trunk and face with sparing of the limbs ([[central obesity]])
| style="background: #F5F5F5;" |Clinical features of [[Cushing's syndrome]] are due to increased levels of [[cortisol]]:
* Proximal muscle weakness
* Rapid [[Obesity|weight gain]], particularly of the [[trunk]] and face with sparing of the [[limbs]] ([[central obesity]])
* Proximal [[muscle weakness]]
* A round face often referred to as a "[[moon face]]"
* A round face often referred to as a "[[moon face]]"
* Excess [[sweating]]
* Excess [[sweating]]
* Headache
* [[Headache]]
* The excess cortisol may also affect other endocrine systems and cause, for example
* The excess [[cortisol]] may also affect other endocrine systems and cause, for example:
** [[Insomnia]]
** [[Insomnia]]
** Reduced [[libido]]
** Reduced [[libido]]
** [[Impotence]]
** [[Impotence]]
** [[Amenorrhoea]]
** [[Amenorrhea]]
** [[Infertility]]
** [[Infertility]]
* Patients frequently suffer various psychological disturbances, ranging from [[Euphoria (emotion)|euphoria]] to [[psychosis]]. [[Clinical depression|Depression]] and [[anxiety]] are also common.
* Patients frequently suffer various [[psychological]] disturbances, ranging from [[Euphoria (emotion)|euphoria]] to [[psychosis]]. [[Clinical depression|Depression]] and [[anxiety]] are also common.
|
| style="background: #F5F5F5;" |
* Dexamethasone suppression test
* [[Dexamethasone suppression test]]
* 24 hour urinary measurement of cortisol
* 24 hour urinary measurement of [[cortisol]]
|
| style="background: #F5F5F5;" |
* Medical management:
* Medical management:
** [[Pasireotide]]
** [[Pasireotide]]
** [[Cabergoline]],
** [[Cabergoline]]
** [[Ketoconazole]]
** [[Ketoconazole]]
** [[Metyrapone]]
** [[Metyrapone]]
Line 97: Line 92:
** [[Mifepristone]]
** [[Mifepristone]]
* Surgical management:
* Surgical management:
** Transsphenoidal pituitary resection
** Transsphenoidal [[Pituitary gland|pituitary]] resection
|-
|-
|[[Hypothyroidism]]
| style="background: #DCDCDC; text-align: center;" |[[Hypothyroidism]]
|Clinical features of [[hypothyroidism]] are due to deficiency of [[thyroxine]]:
| style="background: #F5F5F5;" |Clinical features of [[hypothyroidism]] are due to deficiency of [[thyroxine]]:
* [[Fatigue]]
* [[Fatigue]]
* Cold intolerance
* Cold intolerance
* Decreased sweating
* Decreased [[sweating]]
* [[Hypothermia]]
* [[Hypothermia]]
* Coarse skin
* Coarse [[skin]]
* [[Weight gain]]
* [[Weight gain]]
* [[Hoarseness]]
* [[Hoarseness]]
* [[Goiter]]
* [[Goiter]]
* Fullness in the throat and neck
* Fullness in the throat and neck
* [[Depression]]
* [[Depression]]
* [[Emotional lability]]
* [[Emotional lability]]
* [[Attention deficit]]
* [[Attention deficit]]
|
| style="background: #F5F5F5;" |
* Elevated [[Thyroid-stimulating hormone|TSH]]
* Elevated [[Thyroid-stimulating hormone|TSH]]
* Low [[Thyroxine|T4]]
* Low [[Thyroxine|T4]]
* Low [[Triiodothyronine|T3]]
* Low [[Triiodothyronine|T3]]
* Elevated Anti-thyroid antibodies(TPOAb)
* Elevated anti-thyroid [[antibodies]](anti-TPO)
|[[Levothyroxine]]
| style="background: #F5F5F5;" |
*[[Levothyroxine]]
|-
|-
|[[Chronic renal failure]]
| style="background: #DCDCDC; text-align: center;" |[[Chronic renal failure]]
|There are no pathognomonic symptoms associated with chronic renal failure. Common non-specific symptoms of chronic renal failure includes:
| style="background: #F5F5F5;" |There are no [[pathognomonic]] symptoms associated with [[chronic renal failure]]. Common non-specific symptoms of [[chronic renal failure]] include:
* [[Malaise]]
* [[Malaise]]
* [[nausea]]
* [[Nausea]]
* unintentional [[weight loss]]
* Unintentional [[weight loss]]
* [[pruritus]]
* [[Pruritus]]
* [[lower extremity edema]]
* [[Lower extremity edema]]
* [[sleep disorders]]
* [[Sleep disorders]]
|[[Urinalysis]]:
| style="background: #F5F5F5;" |[[Urinalysis]]:
* [[Albuminuria]]
* [[Albuminuria]]
* [[Hematuria]]
* [[Hematuria]]
* [[Pyuria]]
* [[Pyuria]]
* Red cell or white cell [[casts]] and crystals
* [[Red blood cell|Red cell]] or [[White blood cells|white cell]] [[casts]] and crystals
Fluid and Electrolyte disturbances:
[[Fluid and electrolytes|Fluid and electrolyte]] disturbances:
* [[Hyponatremia]]
* [[Hyponatremia]]
* [[Hyperkalemia]]
* [[Hyperkalemia]]
Line 145: Line 136:
* [[Metabolic acidosis]]
* [[Metabolic acidosis]]
* [[Hypocalcemia]]
* [[Hypocalcemia]]
Endocrine and Metabolic disturbances
[[Endocrine system|Endocrine]] and [[metabolic]] disturbances:
* [[Hyperuricemia]]
* [[Hyperuricemia]]
* [[Hypertriglyceridemia]]
* [[Hypertriglyceridemia]]
Line 151: Line 142:
* [[Vitamin D deficiency]]
* [[Vitamin D deficiency]]
* Increased [[Parathyroid hormone]] levels
* Increased [[Parathyroid hormone]] levels
Hematologic abnormalities
[[Hematologic]] abnormalities:
* [[Normocytic normochromic anemia]]
* [[Normocytic normochromic anemia]]
* [[Lymphocytopenia]]
* [[Lymphocytopenia]]
* [[Leukopenia]]
* [[Leukopenia]]
* [[Thrombocytopenia]]
* [[Thrombocytopenia]]
 
| style="background: #F5F5F5;" |
|
* Medical management:  
* Medical management:  
** [[Blood pressure medication|Blood pressure management]]
** [[Blood pressure medication|Blood pressure management]]
** Control of [[Blood sugar|blood glucose]]
** Control of [[Blood sugar|blood glucose]]
** Protein restriction
** [[Protein]] restriction
** Management of [[anemia]]
** Management of [[anemia]]
** Management of [[electrolyte disturbance]]
** Management of [[electrolyte disturbance]]
Line 168: Line 158:
** [[Kidney transplant]]
** [[Kidney transplant]]
|-
|-
|[[Cirrhosis|Liver disease: Cirrhosis]]
| style="background: #DCDCDC; text-align: center;" |[[Cirrhosis|Liver disease: Cirrhosis]]
|The clinical features of liver cirrhosis are very non-specific. These includes:
| style="background: #F5F5F5;" |The clinical features of liver [[cirrhosis]] are very nonspecific. These include:
* Right upper quadrant [[abdominal pain]]
* [[Right upper quadrant (abdomen)|Right upper quadrant]] [[abdominal pain]]
* [[Fever]]
* [[Fever]]
* [[Fatigue]] and [[weakness]]
* [[Fatigue]] and [[weakness]]
Line 177: Line 167:
* [[Nausea]] and [[vomiting]]
* [[Nausea]] and [[vomiting]]
* [[Weight loss]]
* [[Weight loss]]
* [[Abdominal pain]] and bloating when fluid accumulates in the abdomen
* [[Abdominal pain]] and [[bloating]] when fluid accumulates in the [[abdomen]]
* [[Itching]]
* [[Itching]]
* Menstrual irregularities
* [[Menstrual cycle|Menstrual]] irregularities
|Elevated [[aminotransferases]] ([[Aspartate transaminase|AST]] & [[Alanine transaminase|ALT]])
| style="background: #F5F5F5;" |
Elevated [[alkaline phosphatase]] ([[Alkaline phosphatase|ALP]])
*Elevated [[aminotransferases]] ([[Aspartate transaminase|AST]] & [[Alanine transaminase|ALT]])
 
*Elevated [[alkaline phosphatase]] ([[Alkaline phosphatase|ALP]])
Elevated [[gamma-glutamyl transpeptidase]]
*Elevated [[gamma-glutamyl transpeptidase]]
 
*Elevated [[bilirubin]]
Elevated [[bilirubin]]
*Low [[albumin]]
 
*Elevated [[prothrombin time]]
Low [[albumin]]
*Elevated [[globulin]]
 
*[[Hyponatremia]]
Elevated [[prothrombin time]]
*[[Anemia]]
 
*[[Leukopenia]] and [[neutropenia]]
Elevated [[globulin]]
*[[Thrombocytopenia]]
 
| style="background: #F5F5F5;" |
[[Hyponatremia]]
 
[[Anemia]]
 
[[Leukopenia]] and [[neutropenia]]
 
[[Thrombocytopenia]]
 
|
* Medical management:
* Medical management:
** Treatment is directed directed most of the times towards the treatment of complications like [[ascites]], [[esophageal varices]], [[hepatic encephalopathy]], [[hepatorenal syndrome]], [[spontaneous bacterial peritonitis]].  
** Treatment is usually directed towards the treatment of complications like [[ascites]], [[esophageal varices]], [[hepatic encephalopathy]], [[hepatorenal syndrome]], and [[spontaneous bacterial peritonitis]].  
*** Some chronic constitutional symptoms that should be treated includes:
*** Some chronic constitutional [[symptoms]] that should be treated include:
**** [[Pruritis]]: [[Cholestyramine]] is the drug of choice
**** [[Pruritis]]: [[Cholestyramine]] is the drug of choice
**** [[Hypogonadism]]: Topical [[testosterone]] preparations
**** [[Hypogonadism]]: Topical [[testosterone]] preparations
**** [[Osteoporosis]]: [[Calcium]] and [[vitamin D]]
**** [[Osteoporosis]]: [[Calcium]] and [[vitamin D]]
**** Pain management: [[Non-steroidal anti-inflammatory drug|NSAIDS]], [[celecoxib]], [[opioids]]
**** Pain management: [[Non-steroidal anti-inflammatory drug|NSAIDS]], [[celecoxib]], [[opioids]]
**** Nutrition: Adequate calories, proteins and multivitamin supplementation
**** Nutrition: Adequate [[Calories|caloric]] and [[protein]] intake, and [[multivitamin]] supplementation
* Surgical management: [[Liver transplantation]]
* Surgical management: [[Liver transplantation]]
|-
|-
|[[Seizure|Seizure disorder]]
| style="background: #DCDCDC; text-align: center;" |[[Seizure|Seizure disorder]]
|The clinical feature of [[seizure disorder]] includes:
| style="background: #F5F5F5;" |The clinical features of [[seizure disorder]] may include:
* Change in [[alertness]]; the person cannot remember a period of time
* Change in [[alertness]], orientation and time perception
 
* Mood changes, such as unexplainable fear, panic, joy, or laughter
* Mood changes, such as unexplainable fear, panic, joy, or laughter
* Change in sensation of the skin, usually spreading over the arm, leg, or trunk
* Changes in sensation of the [[skin]], usually spreading over the [[arm]], [[Leg (anatomy)|leg]], or [[trunk]]
* [[Vision]] changes, including seeing flashing lights
* [[Vision]] changes, including seeing flashing lights
* Rarely, [[Hallucination|hallucinations]] (seeing things that aren't there)
* Rarely, [[Hallucination|hallucinations]] (seeing things that aren't there)
* Falling, loss of muscle control, occurs very suddenly
* Falling, loss of [[muscle]] control, occurs very suddenly
* [[Muscle twitching]] that may spread up or down an arm or leg
* [[Muscle twitching]] that may spread up or down an [[arm]] or [[leg]]
* Muscle tension or tightening that causes twisting of the body, head, arms, or legs
* [[Muscle]] tension or tightening that causes twisting of the body, [[head]], [[Arm|arms]], or [[legs]]
* Shaking of the entire body
* Shaking of the entire body
* Tasting a bitter or metallic flavor
* Tasting a bitter or metallic flavor
|[[Electroencephalogram]]
| style="background: #F5F5F5;" |
|
*[[Electroencephalogram]]
| style="background: #F5F5F5;" |
* Medical management:
* Medical management:
** [[Antiepileptics|Antiepileptic]] medications
** [[Antiepileptics|Antiepileptic]] medications
|-
|-
|[[Medication-induced]]
| style="background: #DCDCDC; text-align: center;" |[[Medication-induced]]
|Clinical features of [[hyperprolactinemia]] after a specific period of regular medication ingestion
| style="background: #F5F5F5;" |Clinical features of [[hyperprolactinemia]] after a specific period of regular medication ingestion
|Discontinuation of the medication for 3 days and remeasurement of prolactin levels<ref name="pmid21296991">{{cite journal| author=Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA et al.| title=Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. | journal=J Clin Endocrinol Metab | year= 2011 | volume= 96 | issue= 2 | pages= 273-88 | pmid=21296991 | doi=10.1210/jc.2010-1692 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21296991  }}</ref>
| style="background: #F5F5F5;" |
|Change to alternate medication
*Discontinuation of the medication for 3 days and remeasurement of [[prolactin]] levels<ref name="pmid21296991">{{cite journal| author=Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA et al.| title=Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. | journal=J Clin Endocrinol Metab | year= 2011 | volume= 96 | issue= 2 | pages= 273-88 | pmid=21296991 | doi=10.1210/jc.2010-1692 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21296991  }}</ref>
| style="background: #F5F5F5;" |
*Change to alternate medication
|}
|}


Line 240: Line 223:
{{WikiDoc Help Menu}}
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}
{{WikiDoc Sources}}
[[Category:Disease]]
[[Category:Disease]]
[[Category:Neuroendocrinology]]
[[Category:Neuroendocrinology]]
[[Category:Oncology]]
[[Category:Medicine]]
[[Category:Endocrinology]]
[[Category:Up-To-Date]]
[[Category:Neurology]]
[[Category:Neurosurgery]]

Latest revision as of 23:49, 29 July 2020

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Anmol Pitliya, M.B.B.S. M.D.[2]

Overview

Prolactinoma must be differentiated from other causes of hyperprolactinemia that may present as galactorrhea, amenorrhea, (in females) and infertility (in both males and females). Causes of hyperprolactinemia can be categorized as physiological, pathological, and medication-induced.

Differential Diagnosis

Prolactinoma must be differentiated from other causes of hyperprolactinemia that may present as galactorrhea, amenorrhea, (in females) and infertility (in both males and females) including:

Disease Clinical Findings Laboratory Findings Management
Somatotroph adenoma:

Acromegaly

Clinical features of acromegaly are due to high level of human growth hormone (hGH):
Corticotroph adenoma:

Cushing's syndrome

Clinical features of Cushing's syndrome are due to increased levels of cortisol:
Hypothyroidism Clinical features of hypothyroidism are due to deficiency of thyroxine:
Chronic renal failure There are no pathognomonic symptoms associated with chronic renal failure. Common non-specific symptoms of chronic renal failure include: Urinalysis:

Fluid and electrolyte disturbances:

Endocrine and metabolic disturbances:

Hematologic abnormalities:

Liver disease: Cirrhosis The clinical features of liver cirrhosis are very nonspecific. These include:
Seizure disorder The clinical features of seizure disorder may include:
  • Change in alertness, orientation and time perception
  • Mood changes, such as unexplainable fear, panic, joy, or laughter
  • Changes in sensation of the skin, usually spreading over the arm, leg, or trunk
  • Vision changes, including seeing flashing lights
  • Rarely, hallucinations (seeing things that aren't there)
  • Falling, loss of muscle control, occurs very suddenly
  • Muscle twitching that may spread up or down an arm or leg
  • Muscle tension or tightening that causes twisting of the body, head, arms, or legs
  • Shaking of the entire body
  • Tasting a bitter or metallic flavor
Medication-induced Clinical features of hyperprolactinemia after a specific period of regular medication ingestion
  • Discontinuation of the medication for 3 days and remeasurement of prolactin levels[13]
  • Change to alternate medication

References

  1. Rigg LA, Lein A, Yen SS (1977). "Pattern of increase in circulating prolactin levels during human gestation". Am J Obstet Gynecol. 129 (4): 454–6. PMID 910825.
  2. Levy A (2004). "Pituitary disease: presentation, diagnosis, and management". J Neurol Neurosurg Psychiatry. 75 Suppl 3: iii47–52. doi:10.1136/jnnp.2004.045740. PMC 1765669. PMID 15316045.
  3. Snyder PJ, Jacobs LS, Utiger RD, Daughaday WH (1973). "Thyroid hormone inhibition of the prolactin response to thyrotropin-releasing hormone". J Clin Invest. 52 (9): 2324–9. doi:10.1172/JCI107421. PMC 333037. PMID 4199418.
  4. Sievertsen GD, Lim VS, Nakawatase C, Frohman LA (1980). "Metabolic clearance and secretion rates of human prolactin in normal subjects and in patients with chronic renal failure". J Clin Endocrinol Metab. 50 (5): 846–52. doi:10.1210/jcem-50-5-846. PMID 7372775.
  5. Jha SK, Kannan S (2016). "Serum prolactin in patients with liver disease in comparison with healthy adults: A preliminary cross-sectional study". Int J Appl Basic Med Res. 6 (1): 8–10. doi:10.4103/2229-516X.173984. PMC 4765284. PMID 26958514.
  6. Ben-Menachem, Elinor (2006). "Is Prolactin a Clinically Useful Measure of Epilepsy?". Epilepsy Currents. 6 (3): 78–79. doi:10.1111/j.1535-7511.2006.00104.x. ISSN 1535-7597.
  7. Trimble MR (1978). "Serum prolactin in epilepsy and hysteria". Br Med J. 2 (6153): 1682. PMC 1608938. PMID 737437.
  8. David SR, Taylor CC, Kinon BJ, Breier A (2000). "The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia". Clin Ther. 22 (9): 1085–96. doi:10.1016/S0149-2918(00)80086-7. PMID 11048906.
  9. McCallum RW, Sowers JR, Hershman JM, Sturdevant RA (1976). "Metoclopramide stimulates prolactin secretion in man". J Clin Endocrinol Metab. 42 (6): 1148–52. doi:10.1210/jcem-42-6-1148. PMID 777023.
  10. Sowers JR, Sharp B, McCallum RW (1982). "Effect of domperidone, an extracerebral inhibitor of dopamine receptors, on thyrotropin, prolactin, renin, aldosterone, and 18-hydroxycorticosterone secretion in man". J Clin Endocrinol Metab. 54 (4): 869–71. doi:10.1210/jcem-54-4-869. PMID 7037817.
  11. Steiner J, Cassar J, Mashiter K, Dawes I, Fraser TR, Breckenridge A (1976). "Effects of methyldopa on prolactin and growth hormone". Br Med J. 1 (6019): 1186–8. PMC 1639736. PMID 1268617.
  12. Fearrington EL, Rand CH, Rose JD (1983). "Hyperprolactinemia-galactorrhea induced by verapamil". Am J Cardiol. 51 (8): 1466–7. PMID 6682619.
  13. Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA; et al. (2011). "Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline". J Clin Endocrinol Metab. 96 (2): 273–88. doi:10.1210/jc.2010-1692. PMID 21296991.

Template:WikiDoc Sources